ISI Group analyst Mark Schoenebaum
look's to be from a survey of biotech buy-sides that this Mark S conducts. and i agree w/ dmatt, these afflictions don't even relate to the current trials underway. it's equivalent to fixating on a loose brick in the top corner of a skyscraper.